이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AREV Life Sciences Global 과거 수익 실적

과거 기준 확인 0/6

AREV Life Sciences Global은 연평균 48.7%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 51%의 비율로 수입이 증가했습니다. 매출은 연평균 10.2%의 비율로 증가했습니다.

주요 정보

48.7%

수익 성장률

51.5%

EPS 성장률

Pharmaceuticals 산업 성장	23.1%
매출 성장률	10.2%
자기자본 수익률	n/a
순이익	-555.8%
최근 수익 업데이트	30 Sep 2022

최근 과거 실적 업데이트

Recent updates

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Jan 02

수익 및 비용 분석

AREV Life Sciences Global 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

CNSX:AREV 수익, 비용 및 수입 (CAD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 22	-1	2	0
30 Jun 22	-1	2	0
31 Mar 22	-1	2	0
31 Dec 21	-1	2	0
30 Sep 21	-2	1	0
30 Jun 21	-2	1	0
31 Mar 21	-2	1	0
31 Dec 20	-1	1	0
30 Sep 20	-1	0	0
30 Jun 20	-1	1	0
31 Mar 20	-2	2	0
31 Dec 19	-3	2	1
30 Sep 19	-10	2	1
30 Jun 19	-10	3	1
31 Mar 19	-9	1	1
31 Dec 18	-8	1	0
30 Sep 18	-2	1	0
30 Jun 18	-1	1	0
31 Mar 18	-1	1	0
31 Dec 17	-1	1	0
30 Sep 17	-1	1	0
30 Jun 17	0	0	0
31 Mar 17	0	0	0
31 Dec 16	0	0	0
30 Sep 16	0	0	0
30 Jun 16	0	0	0
31 Mar 16	0	0	0
31 Dec 15	0	0	0
30 Sep 15	0	0	0
30 Jun 15	0	0	0
31 Mar 15	0	0	0
31 Dec 14	0	0	0
30 Sep 14	0	0	0
30 Jun 14	0	0	0
31 Mar 14	0	0	0
31 Dec 13	0	0	0
30 Sep 13	0	0	0
30 Jun 13	0	0	0
31 Mar 13	0	0	0

양질의 수익: AREV 은(는) 현재 수익성이 없습니다.

이익 마진 증가: AREV 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 지난 5년간 AREV 의 전년 대비 수익 성장률이 긍정적인지 판단하기에는 데이터가 부족합니다.

성장 가속화: 현재 수익성이 없기 때문에 AREV 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: AREV 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 39.8% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: AREV 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

AREV Life Sciences Global 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

Recent updates

AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024

No independent directors

No independent directors

No independent directors

AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board

No independent directors

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Chairman & CEO recently bought CA$59k worth of stock

No independent directors

AREV Life Sciences Global Corp. Announces Management Changes

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory Board

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

No independent directors

AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of Directors

AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating Officer

AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory Committee

AREV Life Sciences Settles Pending Litigation with Harvey

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.

Chairman & CEO exercised options to buy CA$200k worth of stock.

Chairman & CEO recently sold CA$125k worth of stock

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs

AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in funding

Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate Development

AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of Directors

AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory Board

AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral Pathogens

New 90-day high: CA$0.42

AREV Appoints Dr. Roscoe Moore to Join the Advisory Board

AREV NanoTec Brands Inc. Corporate Update on Latest Innovation

AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory Board

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in funding

AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLC

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

New 90-day high: CA$0.22

Chairman & CEO recently sold CA$261k worth of stock

AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune Boost

AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP Marketing

First half earnings released

AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in funding

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기